Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

GenoLogics And Illumina Sign Deal

February 9, 2011 6:57 am | News | Comments

GenoLogics announced it has signed a worldwide co-selling agreement with Illumina, Inc. Under terms of the deal, Illumina will market a version of the Geneus LIMS that is pre-configured for Illumina’s NGS instruments and TruSeq sample preparation kits.


FDA Approves CeNeRx IND

February 9, 2011 6:50 am | News | Comments

CeNeRx is now preparing to launch further Phase 1 studies of CXB909 targeting chemotherapy-induced peripheral neuropathy as its first potential indication. CXB909 is believed to promote synthesis of acetylcholine.


PolyMedix Starts New Trial for PMX-60056

February 9, 2011 6:46 am | News | Comments

PolyMedix, Inc. has initiated a Phase 2 clinical trial to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing percutaneous coronary intervention procedures.


Stem Cells Used to Treat Parkinson's

February 9, 2011 6:38 am | News | Comments

Successful intranasal delivery of stem cells to the brains of rats with Parkinson disease yielded significant improvement in motor function and reversed the dopamine deficiency characteristic of the disease.


Immune Suppression to Speed Wound Healing?

February 9, 2011 6:31 am | News | Comments

Researchers are reporting on a promising new approach to treating diabetic wounds, bed sores, chronic ulcers and other slow-to-heal wounds. It may be possible to speed healing by suppressing certain immune system cells.


Peptide Stapling Breakthrough Could Lead to Better Drugs

February 9, 2011 6:28 am | News | Comments

Researchers have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes. The discovery could help speed the development of peptide-based drugs against diseases including cancer.


Dutasteride Not Cost-Effective in Cancer Prevention

February 9, 2011 6:25 am | News | Comments

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease. Investigators found that the annual cost of $1,400 is impractical when compared to the marginal impact on survival and quality of life.


FDA Approves Update to REYATAZ Label

February 9, 2011 6:18 am | News | Comments

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved an update to the labeling for REYATAZ to include dose recommendations in HIV-infected pregnant women.


Qnaze Meets Study Goals

February 9, 2011 6:14 am | News | Comments

Teva Pharmaceutical Industries Ltd. said its allergy drug Qnaze met its goal in a late-stage study that tested its ability to treat year-round allergies. Teva said the clinical trial showed Qnaze was more effective than a placebo at treating nasal allergy symptoms.


FDA Pushes to Accelerate Device Review

February 9, 2011 6:11 am | News | Comments

Federal health officials are proposing a plan that would speed up the approval of innovative medical devices that have the potential to dramatically improve patients' lives.


Sanofi Profits Plummet 64% in Q4

February 9, 2011 6:09 am | News | Comments

Sanofi-Aventis said that hefty new restructuring costs caused its net profit to slump 64 percent in the fourth quarter, amid continued uncertainty over the fate of its nearly $20 billion bid for U.S. biotechnology firm Genzyme Corp.


BD to Acquire Accuri

February 8, 2011 8:46 am | News | Comments

BD (Becton, Dickinson and Company), a leading global medical technology company, announced that it signed a definitive agreement to acquire Accuri Cytometers, Inc., a company that develops and manufactures personal flow cytometers for researchers.


Motor Neuron Progenitors

February 8, 2011 7:32 am | Product Releases | Comments

The MotorPlate Human ESC-derived Motor Neuron Progenitor products from Lonza and California Stem Cell are functional, adherent motor neuron progenitors seeded in 96-well plates and shipped to customers fresh and ready-to-use with optimized media.


DNA Analysis Software

February 8, 2011 7:26 am | Product Releases | Comments

QIAGEN has launched ScreenGel software for convenient DNA fragment and RNA analysis with the QIAxcel multicapillary gel electrophoresis systems. The software combines flexibility for researchers with standardized and reproducible operations in the lab.


Molecular Profiles Buys Microdoser

February 8, 2011 7:18 am | News | Comments

Molecular Profiles, a leading pharmaceutical development service provider, announces the continued expansion of its manufacturing capabilities with the recent purchase of the Xcelodose 120S system.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.